Aviragen Therapeutics Revenue and Competitors

Atlanta, GA USA

Location

N/A

Total Funding

Research

Industry

Estimated Revenue & Valuation

  • Aviragen Therapeutics's estimated annual revenue is currently $3.1M per year.(i)
  • Aviragen Therapeutics's estimated revenue per employee is $81,600

Employee Data

  • Aviragen Therapeutics has 38 Employees.(i)
  • Aviragen Therapeutics grew their employee count by -3% last year.

Aviragen Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1M16-11%N/AN/A
#2
$6.4M7063%N/AN/A
#3
$3.1M38-3%N/AN/A
#4
$3.8M46N/AN/AN/A
#5
$3.7M452%N/AN/A
#6
$2.5M3111%N/AN/A
#7
$2.9M39-19%$33.4MN/A
#8
$22.2M198-2%N/AN/A
#9
$0.2M4N/AN/AN/A
#10
$3.3M418%N/AN/A
Add Company

What Is Aviragen Therapeutics?

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplatovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papillomavirus types 6 & 11.

keywords:N/A

N/A

Total Funding

38

Number of Employees

$3.1M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.6M38-5%N/A
#2
$4.4M38-10%N/A
#3
$10.7M380%N/A
#4
$10.6M383%N/A
#5
$7.4M383%N/A